Conjugates of Degraded and Oxidized Hydroxyethyl Starch and Sulfonylureas: Synthesis, Characterization, and in Vivo Antidiabetic Activity
- 29 December 2014
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 26 (1) , 120-127
Abstract
Orally administered drugs usually face the problem of low water solubility, low permeability, and less retention in bloodstream leading to unsatisfactory pharmacokinetic profile of drugs. Polymer conjugation has attracted increasing interest in the pharmaceutical industry for delivering such low molecular weight (Mw) drugs as well as some complex compounds. In the present work, degraded and oxidized hydroxyethyl starch (HES), a highly biocompatible semisynthetic biopolymer, was used as a drug carrier to overcome the solubility and permeability problems. The HES was coupled with synthesized N-arylsulfonylbenzimidazolones, a class of sulfonylurea derivatives, by creating an amide linkage between the two species. The coupled products were characterized using GPC, FT-IR, 1H NMR, and 13C NMR spectroscopy. The experiments established the viability of covalent coupling between the biopolymer and N-arylsulfonylbenzimidazolones. The coupled products were screened for their in vivo antidiabetic potential on male albino rats. The coupling of sulfonylurea derivatives with HES resulted in a marked increase of the hypoglycemic activity of all the compounds. 2,3-Dihydro-3-(4-nitrobenzensulfonyl)-2-oxo-1H-benzimidazole coupled to HES10100 was found most potent with a 67% reduction in blood glucose level of the rats as compared to 41% reduction produced by tolbutamide and 38% by metformin.Keywords
This publication has 23 references indexed in Scilit:
- Selective degradation, oxidation, and characterization of hydroxyethyl starch for potential use as a drug carrierStarch - Stärke, 2012
- Pharmacokinetics and safety of 6 % hydroxyethyl starch 130/0.4 in healthy male volunteers of Japanese ethnicity after single infusion of 500 ml solutionJournal of Anesthesia, 2012
- Multimeric, Multifunctional Derivatives of Poly(ethylene glycol)Polymers, 2011
- Polymer–drug conjugation, recent achievements and general strategiesProgress in Polymer Science, 2007
- Volume Replacement Therapy during Major Orthopedic Surgery Using Voluven® (Hydroxyethyl Starch 130/0.4) or HetastarchAnesthesiology, 2007
- Targeted polymeric micelles for delivery of poorly soluble drugsCellular and Molecular Life Sciences, 2004
- Volume Efficacy and Reduced Influence on Measures of Coagulation Using Hydroxyethyl Starch 130/0.4 (6%) with an Optimised in???Vivo???Molecular Weight in Orthopaedic SurgeryDrugs in R&D, 2004
- Voluven®, a Lower Substituted Novel Hydroxyethyl Starch (HES 130/0.4), Causes Fewer Effects on Coagulation in Major Orthopedic Surgery than HES 200/0.5Anesthesia & Analgesia, 2001
- Peptide and protein PEGylationBiomaterials, 2001
- Polyethylene glycol-induced pancreatitisGastrointestinal Endoscopy, 2000